Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | F2 | P00734 | 1/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 1/20 | 0.65 |
| ▸ | DRD1 | P21728 | 1/20 | 0.65 |
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.65 |
| ▸ | DRD3 | P35462 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30503638 | 0.83 | PLAU (1.00) | PLAULMNAMEN1F2CHRM2 | |
| SCHEMBL3412309 | 0.83 | PLAU (1.00) | PLAULMNAMEN1F2CHRM2 | |
| SCHEMBL24954764 | 0.81 | LMNA (0.60) | PLAULMNAMEN1F2CHRM2 | |
| Proflavine SCHEMBL27386 | 0.79 | KMT2A (1.00) | PLAULMNAMEN1F2CHRM2 | |
| Proflavine SCHEMBL29600097 | 0.79 | KMT2A (1.00) | PLAULMNAMEN1F2CHRM2 | |
| Proflavine SCHEMBL10380090 | 0.77 | KMT2A (0.95) | PLAULMNAMEN1F2CHRM2 | |
| Proflavine SCHEMBL664629 | 0.77 | KMT2A (0.95) | PLAULMNAMEN1F2CHRM2 | |
| Proflavine SCHEMBL865664 | 0.77 | KMT2A (0.95) | PLAULMNAMEN1F2CHRM2 | |
| SCHEMBL19405275 | 0.76 | BACE1 (0.57) | PLAUBACE1NCF1NOS2NCK1 | |
| SCHEMBL23453134 | 0.76 | BACE1 (0.57) | PLAUBACE1NCF1NOS2NCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952380-B2 | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | LUPIN LIMITED (IN) | 2024-04-09 | — | — | US | disclosed |
| US-20230332145-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230167450-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230158156-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023001133-A1 | PRMT5 INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2023-01-26 | — | — | WO | disclosed |
| US-20220267339-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | LUPIN LIMITED (IN) | 2022-08-25 | — | — | US | disclosed |
| WO-2021262596-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| CN-112978709-A | Carbon quantum dot precursor composition, carbon quantum dot and preparation method thereof | 中国科学院大连化学物理研究所 | 2021-06-18 | — | — | CN | disclosed |
| EP-1058549-A4 | THROMBIN OR FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6602871-B2 | Anticoagulants; compounds of given formula: several types of nitrogen containing heterocycles such as perhydroindolizine, piperazine, pyrimidine | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-08-05 | — | — | US | disclosed |
| US-20020115854-A1 | Thrombin or factor Xa inhibitors | LAM PATRICK Y S (US) | 2002-08-22 | — | — | US | disclosed |
| EP-1058549-A1 | THROMBIN OR FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-12-13 | — | — | EP | disclosed |
| WO-2000038683-A1 | THROMBIN OR FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158156-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | EFTUD2, SNRPE, DDX21 | PLAU 927/4885LMNA 2634/4885MEN1 2981/4885 |
| US-20220267339-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PLAU 3657/4885LMNA 2045/4885MEN1 1296/4885 |
| US-11952380-B2 | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | PLAU 3657/4885LMNA 2045/4885MEN1 1296/4885 |
| US-20020115854-A1 | Thrombin or factor Xa inhibitors | SERPINC1, TFPI, SPINT2 | PLAU 40/4885LMNA 902/4885MEN1 1557/4885 |
| US-20230332145-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | EFTUD2, DDX21, SNRPE | PLAU 1578/4885LMNA 2641/4885MEN1 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.